Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29225823 | 0.89 | LIPG (0.37) | LPLLIPGIRAK4CD44CA1 | |
| SCHEMBL29897342 | 0.86 | LPL (0.41) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL20722870 | 0.86 | LPL (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL29897387 | 0.86 | LPL (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL5840223 | 0.86 | CD44 (0.47) | LPLLIPGIRAK4P2RX7CD44 | |
| SCHEMBL23301057 | 0.86 | LPL (0.41) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL18569315 | 0.86 | LPL (0.38) | LPLLIPGIRAK4P2RX7 | |
| SCHEMBL31185820 | 0.84 | LPL (0.38) | LPLLIPGIRAK4P2RX7CA1 | |
| SCHEMBL26647695 | 0.83 | CSF1R (0.38) | LPLLIPGCYP1A2CA1CA2 | |
| SCHEMBL12665647 | 0.82 | ALDH1A1 (0.46) | LPLLIPGIRAK4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059996-A | Organic metal compound and organic electroluminescent device comprising same | 吉林奥来德光电材料股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036809-A | Organic metal compound and organic electroluminescent device comprising same | 吉林奥来德光电材料股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-118845703-A | High-permeability polymer nanocapsule, and preparation method and application thereof | 浙江大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| CN-116354993-A | Reactive Oxygen Species (ROS) responsive cations and their use in siRNA delivery | 中国科学院合肥物质科学研究院 | 2023-06-30 | — | — | CN | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2014176187-A1 | PYRIDYLDIAMIDE METAL CATALYSTS AND PROCESSES TO PRODUCE POLYOLEFINS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20140316089-A1 | Pyridyldiamide Metal Catalysts and Processes to Produce Polyolefins | EXXONMOBIL CHEMICAL PATENTS INC. | 2014-10-23 | — | — | US | disclosed |
| US-8754241-B2 | Organic compound and electrochromic element having the same | CANON KABUSHIKI KAISHA (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20130190513-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC ELEMENT HAVING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-2013060411-A1 | HYPERBRANCHED POLYMERS, METHODS FOR PRODUCING SAME, AND USE OF SAME IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2013-05-02 | — | — | WO | disclosed |
| CN-100491323-C | Biaryloxymethylarenecarboxylic acids compound | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | LPL 256/4885LIPG 120/4885IRAK4 3347/4885 |
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | LPL 4166/4885LIPG 3534/4885IRAK4 3902/4885 |
| US-20130190513-A1 | NOVEL ORGANIC COMPOUND AND ELECTROCHROMIC ELEMENT HAVING THE SAME | EPB41, CNOT1, CYP4F11 | LPL 4122/4885LIPG 3334/4885IRAK4 3566/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | LPL 256/4885LIPG 120/4885IRAK4 3347/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | LPL 256/4885LIPG 120/4885IRAK4 3347/4885 |
| US-20140336190-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | LPL 3456/4885LIPG 4316/4885IRAK4 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.